Apolipoprotein E polymorphism and gallstones. 1996

A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
Lipid Clinic, Hospital Clínic i Provincial, Barcelona, Spain.

OBJECTIVE Apolipoprotein (apo) E is a genetically polymorphic protein influencing lipoprotein metabolism and the risk of both atherosclerosis and Alzheimer's disease. As opposed to common apo E3, apo E2 decreases and apo E4 increases hepatic lipoprotein uptake; hence, apo E4 could promote gallstone formation by increasing hepatic and biliary cholesterol concentrations. This study was designed to evaluate whether apo E polymorphism is related to gallstone risk. METHODS apo E phenotype was determined in subjects older than 40 years of age (160 with and 125 without gallstones) and in 61 patients with cholesterol gallstones who underwent cholecystectomy. Bile composition, nucleation time, and gallstone features were analyzed in surgical patients. RESULTS The E4/3 phenotype was enriched in both patients with gallstones and those who underwent cholecystectomy, with significantly (P < 0.006) higher epsilon 4 allele frequencies than in gallstone-free subjects (odds ratio, 2.67 [95% confidence limits, 1.23-5.93] and 3.62 [95% confidence limits, 1.49-8.91], respectively); women, but not men, accounted for these differences. The prevalence of the epsilon 4 allele increased with age in patients with gallstones, whereas the opposite occurred in gallstone-free subjects. Biliary lipid and gallstone cholesterol content tended to increase in the sequence E4 > E3 > E2 in patients who underwent cholecystectomy. CONCLUSIONS Carrying the apo E4 isoform is a genetic risk factor for cholelithiasis in humans, thus adding another adverse effect of apo E polymorphism on health.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D002769 Cholelithiasis Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS). Gallstone Disease,Cholelithiases,Gallstone Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
May 1984, Clinical chemistry,
A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
January 2003, Angiology,
A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
January 1988, Arteriosclerosis (Dallas, Tex.),
A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
March 2001, Nihon rinsho. Japanese journal of clinical medicine,
A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
January 2006, American journal of human biology : the official journal of the Human Biology Council,
A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
January 2013, Annales de biologie clinique,
A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
January 2009, Annals of clinical and laboratory science,
A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
April 2001, The Kaohsiung journal of medical sciences,
A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
September 1993, Lancet (London, England),
A Bertomeu, and E Ros, and D Zambón, and M Vela, and R M Pérez-Ayuso, and E Targarona, and M Trías, and C Sanllehy, and E Casals, and J M Ribó
July 1999, Kidney international. Supplement,
Copied contents to your clipboard!